Literature DB >> 10101005

Proteinase 3, a potent secretagogue in airways, is present in cystic fibrosis sputum.

V Witko-Sarsat1, L Halbwachs-Mecarelli, A Schuster, P Nusbaum, I Ueki, S Canteloup, G Lenoir, B Descamps-Latscha, J A Nadel.   

Abstract

We evaluated the roles of proteinase 3 (PR3) and human neutrophil elastase (HNE), two neutrophil serine proteinases in the mechanisms leading to airway inflammation and hypersecretion in cystic fibrosis (CF). Using specific enzyme-linked immunosorbent assay (ELISA), we found higher levels of PR3 than HNE in sputum from CF patients. Using two inhibitors, ICI (Imperial Chemical Industries) 200,355 (which inhibits both HNE and PR3) and secretory leukoproteinase inhibitor (SLPI) (which inhibits only HNE), we showed that PR3 was enzymatically active in sputum, and its activity, as assessed by SLPI-resistant serine proteinase activity, correlated highly with its antigenic concentration measured by ELISA. Interestingly, sputum pellet-associated serine proteinase activity was mostly due to HNE. PR3 purified from neutrophil azurophil granules triggered airway gland secretion, as measured by the release of radiolabeled molecules from cultured bovine tracheal serous cells pulse-labeled with Na235SO4. This secretory activity was inhibited by ICI 200,355. PR3 concentration in CF sputum was highly correlated with taurine concentration, a reliable marker of airway inflammation and respiratory scores (e.g., FEV1%), whereas no significant correlation was observed with HNE. We verified that Pseudomonas aeruginosa proteinases did not interfere with the assessment of PR3 and HNE. Indeed, the PR3/HNE ratio was greatest in patients chronically infected by P. aeruginosa. We suggest that PR3 may play a role in the hypersecretory process that is characteristic of CF.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10101005     DOI: 10.1165/ajrcmb.20.4.3371

Source DB:  PubMed          Journal:  Am J Respir Cell Mol Biol        ISSN: 1044-1549            Impact factor:   6.914


  29 in total

Review 1.  Factors influencing airway inflammation in chronic obstructive pulmonary disease.

Authors:  A Hill; S Gompertz; R Stockley
Journal:  Thorax       Date:  2000-11       Impact factor: 9.139

2.  SerpinB1 in cystic fibrosis airway fluids: quantity, molecular form and mechanism of elastase inhibition.

Authors:  J Cooley; M K Sontag; F J Accurso; E Remold-O'Donnell
Journal:  Eur Respir J       Date:  2010-09-03       Impact factor: 16.671

Review 3.  Neutrophil elastase, proteinase 3, and cathepsin G as therapeutic targets in human diseases.

Authors:  Brice Korkmaz; Marshall S Horwitz; Dieter E Jenne; Francis Gauthier
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

4.  Important role of neutrophils in the late asthmatic response in mice.

Authors:  Takeshi Nabe; Fusa Hosokawa; Kouki Matsuya; Toyoko Morishita; Ayumu Ikedo; Masanori Fujii; Nobuaki Mizutani; Shin Yoshino; David D Chaplin
Journal:  Life Sci       Date:  2011-04-30       Impact factor: 5.037

Review 5.  Modulating Innate and Adaptive Immunity by (R)-Roscovitine: Potential Therapeutic Opportunity in Cystic Fibrosis.

Authors:  Laurent Meijer; Deborah J Nelson; Vladimir Riazanski; Aida G Gabdoulkhakova; Geneviève Hery-Arnaud; Rozenn Le Berre; Nadège Loaëc; Nassima Oumata; Hervé Galons; Emmanuel Nowak; Laetitia Gueganton; Guillaume Dorothée; Michaela Prochazkova; Bradford Hall; Ashok B Kulkarni; Robert D Gray; Adriano G Rossi; Véronique Witko-Sarsat; Caroline Norez; Frédéric Becq; Denis Ravel; Dominique Mottier; Gilles Rault
Journal:  J Innate Immun       Date:  2016-03-18       Impact factor: 7.349

Review 6.  Neutrophil elastase inhibitors.

Authors:  William C Groutas; Dengfeng Dou; Kevin R Alliston
Journal:  Expert Opin Ther Pat       Date:  2011-01-16       Impact factor: 6.674

Review 7.  Airway inflammation in chronic obstructive pulmonary disease.

Authors:  Nikolaos Angelis; Konstantinos Porpodis; Paul Zarogoulidis; Dionysios Spyratos; Ioannis Kioumis; Antonis Papaiwannou; Georgia Pitsiou; Kosmas Tsakiridis; Andreas Mpakas; Stamatis Arikas; Theodora Tsiouda; Nikolaos Katsikogiannis; Ioanna Kougioumtzi; Nikolaos Machairiotis; Michael Argyriou; George Kessisis; Konstantinos Zarogoulidis
Journal:  J Thorac Dis       Date:  2014-03       Impact factor: 2.895

8.  Characterization of immunologic properties of a second HLA-A2 epitope from a granule protease in CML patients and HLA-A2 transgenic mice.

Authors:  Simon F Lacey; Corinna La Rosa; Teodora Kaltcheva; Tumul Srivastava; Aprille Seidel; Wendi Zhou; Ravindra Rawal; Katharine Hagen; Aparna Krishnan; Jeff Longmate; Helen A Andersson; Lisa St John; Ravi Bhatia; Vinod Pullarkat; Stephen J Forman; Laurence J N Cooper; Jeffrey Molldrem; Don J Diamond
Journal:  Blood       Date:  2011-06-30       Impact factor: 22.113

9.  Antiproteases as therapeutics to target inflammation in cystic fibrosis.

Authors:  Derek J Quinn; Sinéad Weldon; Clifford C Taggart
Journal:  Open Respir Med J       Date:  2010-03-30

Review 10.  Proteases and antiproteases in chronic neutrophilic lung disease - relevance to drug discovery.

Authors:  Catherine M Greene; Noel G McElvaney
Journal:  Br J Pharmacol       Date:  2009-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.